Prostate Cancer Hormonal Treatment And Treatment Of Advanced Disease

This textbook summarizes the state of the art in the management of locally advanced and metastatic prostate cancer with the aim of providing the knowledge required for optimal treatment decision making in individual cases. Readers will find comprehensive coverage of the latest developments in surgery, radiotherapy, androgen deprivation therapy (ADT), chemotherapy, and immunotherapy. The role of the hormonal therapies abiraterone and enzalutamide and docetaxel-based chemotherapy in castration-resistant prostate cancer and hormone-sensitive metastatic disease is carefully evaluated. Among the other therapies discussed are LHRH agonists and antagonists, cabazitaxel, radium-223, and various novel agents still under clinical trials. The section on surgical approaches addresses, among other topics, the use of robot-assisted radical prostatectomy, pelvic lymphadenectomy, and the benefits of adjuvant and neoadjuvant therapy. The current role of external beam radiotherapy, alone or in combination with ADT and brachytherapy, for locally advanced disease is reviewed. Management of Advanced Prostate Cancer will be a valuable resource for practitioners at all levels of expertise.

It has been recognized for many years that cancers originating in the breast and prostate gland are frequently 'endocrine-dependent. ' Traditional thera pies included surgical endocrine ablative procedures or pharmacologic hor mone administration, both designed to antagonize the stimulatory effects of sex steroid hormones. In the past decade, several new treatment strategies for these tumors have emerged from basic studies in reproductive biology and mechanisms of action of steroid hormones. In some instances, these new treatments have elimin ated or reduced the need for major surgical ablative procedures or for toxic hormone therapy. The clinical role for other new treatments has not yet been clearly defined, although exciting preliminary data from recent clinical trials are now available. Thus, an objective review of the current status of these new therapeutic approaches is of interest. In this volume we have attempted to provide an in-depth review of both basic and clinical research involving several new treatment strategies for breast and prostate cancer. The first three chapters summarize preclinical and clinical studies of the luteinizing hormone-releasing hormone analogues, which can be used effectively to induce 'medical castration. ' Chapters 4, 5, and 6 review the rationale and clinical use of the compounds known collec tively as the aromatase inhibitors, which can also be used to suppress sex steroid hormone levels. Antiestrogen mechanism of action and its clinical implications for the design of innovative treatment approaches is considered in chapters 7 and 8.

Information + Taking Control = Best Outcome is the theme running throughout this short, superbly illustrated workbook. Designed to help patients equip themselves with the best information about metastatic prostate cancer, it covers: • how prostate disease spreads and where it can spread to • a summary of diagnostic tests with detailed explanations to aid understanding of PSA levels, staging and Gleason score • all the hormone treatment options and their side effects • what to expect from the disease itself • how to manage key symptoms such as bone pain, urinary problems and fatigue • the treatment options when hormone treatment stops working • useful advice on diet, exercise, and getting the right support • a frank discussion of end of life care • a concise overview of the latest research in this area. With FastTests to test patients' understanding of their condition, handy checklists and plenty of space for patients and their doctors, nurses and family to write notes, this concise, easy-to-read resource will help patients get organized so that they are better equipped to ask the right questions and have more meaningful discussions about their treatment. Ultimately, it will help them make the best decisions about their care. Contents: • Information + Taking Control = Best Outcome • What is metastatic prostate cancer? • What do my test results mean? • Why is my cancer staged? • How will the disease affect me? • How is metastatic prostate cancer treated? • What is available after hormone therapy? • What are the side effects of hormone treatment? • What can I do to help myself? • Monitoring the effects of therapy • Treatment when myeloma returns • End of life care • What is the latest research in this area? • Useful resources

This comprehensive and easy-to-read monograph is an authoritative update on clinical prostate cancer. It has been prepared by an international, multidisciplinary team at the invitation of the International Prostate Health Council think tank. A particular strength of the book is its presentation of the therapeutic options for patients with localized and advanced disease, including hormonal treatment.

This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnic variation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.

"Androgen deprivation therapy is the main treatment for locally advanced and metastatic prostate cancer. It is a very effective treatment, but it has major impact on many aspects of men's health. Thousands of articles have been dedicated to that subject. This book distills these down and provides a comprehensive understanding and path forward for the many challenges associated with androgen deprivation therapy." - David Crawford, M.D., Professor of Urology, University of California San Diego "As someone who has treated men with prostate cancer for over 25 years, I recognize the burden of care of the patients and their loved ones. This book provides excellent tips on how to deal with the disease. I have used prior versions for many years in my practice and wholly endorse this new version. It’s a must read!" - Neil Fleshner, MD, Chair of Urology, University of Toronto Ontario, and Love Chair in Prostate Cancer Prevention, Princess Margaret Cancer Centre, Toronto, Ontario Androgen Deprivation Therapy is the only guide written exclusively about the side effects of hormone therapy. The authors have collaborated with the European Association of Urology to produce this specially revised new edition to serve men affected by ADT across the globe. This comprehensive workbook for prostate cancer patients and their loved ones is filled with practical advice from experts in the field. The book covers a wealth of strategies to help men cope with ADT and maintain a good quality of life while on this treatment. It is not only an informational manual, but a guide for both patients and partners about ways to make changes in their lives that can keep them healthy and positive when the patient is on ADT. New to this Edition: Updates on the primary drugs used to treat prostate cancer with tables for common brand names worldwide. Updates on the physical side effects of ADT, such as hot flashes, weight gain, muscle loss and fatigue—plus management strategies. Expanded information on exercise and nutrition for men diagnosed with prostate cancer. Expanded information on the psychological and relational impact of ADT on both patients and their partners, with strategies to maintain intimacy despite reduced libido and difficulties with erections. Expanded discussion on dealing with emotional side effects, such as mood swings and depression. Exercises, activities, worksheets, and other tools to promote discussion and inspire behavioral changes that can reduce the burden of ADT. Officially endorsed by the European Association of Urology and the Canadian Urological Association.